Enliven Therapeutics, Inc.ELVNNASDAQ
Loading
EPS Growth Under PressureDecelerating
Percentile Rank50
5Y CAGR-31.2%
Studio
Year-over-Year Change

Year-over-year earnings per share growth rate

5Y CAGR
-31.2%/yr
Long-term compound
Percentile
P50
Within normal range
vs 5Y Ago
0.2x
Contraction
Streak
2 yr
Consecutive declineDecelerating
PeriodValue
20253.17%
20245.97%
202366.67%
2022-90.22%
202126.45%
202020.63%
2019-107.25%
20180.00%
20170.00%